NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
Clinical Trials
6 trialsNCT05164250 2025-11-10
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Approved for marketing
NCT05463939 2025-06-15
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Janssen Research & Development, LLC
Approved for marketing
NCT01632826 2019-11-12
PEXIUS
Celgene
Approved for marketing
NCT02477891 2019-01-15
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT01410500 2017-05-02
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Amgen
Approved for marketing